The Potential Application of Natural Ingredient Ivy Extract Hederagenin in Health Products

As のleading supplier specialising でhigh-quality plant extracts, Green Spring Technology continues to focus on natural active ingredients with marketpotentiアルRecent scientific studies have focused on hederagenin—のnatural pentacyclic triterpenoid compound とits derivatives derived from plants such としてChinese ivy—revealing its excellent health application prospects とproviding strong scientific support for formula innovation でのfields のhealth supplements, functional foods, とbeverages.

Hederageninis a pentacyclic triterpenoid compound primarily derived from plants such as Chinese ivy, Cynanchum atratum, Patrinia scabiosaefolia, Paeonia lactiflora, and Acanthopanax senticosus, typically existing in the form のsaponins or saponins [1]。Hederageninextracted from ivy exhibits various biological activities.

1 Research on the relationship between Hederageninand inflammatory responses

Experimental evidence indicates that Hederagenin can effectively downregulate the expression のmultiple pro-inflammatory cytokines (such as TNF-α, IL-6, TGF-β1), which play important roles in 慢性inflammation and the progression of various diseases.

Inflammation is a complex physiological response of the body to inflammatory factors, involving multiple cellular and molecular mechanisms. Zhang ら[2] found that Hederagenin may contribute to respiratory health and is associated with the regulation of the transient 受容体potential (TRP) channel pathway.

Li etアル[3] explored the potential association between Hederagenin and the NF-κB signalling pathway. Experimental data suggest that this compound may participate in 規制the cellular localisation of NF-κB and Smads proteins and may influence the expression levels of downstream molecules such as transforming growth factor β1 (TGF-β1). These findings provide new insights into the mechanisms underlying Hederagenin's role in inflammatory responses.

In the study によってMa etアル[4], interactions between Hederagenin and the Ras protein/Jun N-terminal kinase/T-cell transcription factor 4 signalling axis were observed. Experimental data showed that the expression levels of factors such as tumour necrosis factor α, IL-6, transforming growth factor β1, and connective tissue growth factor in the serum of rats treated with this compound exhibited a downward trend, while the pathological characteristics of lung tissue also changed.

Wang and 趙[5] explored the potential association between Hederagenin and the NOD-likereceptor protein 3 inflammasome and NF-κB pathway. Experimental results indicate that this compound may influence the phosphorylation process of the NF-κB pathway and is associated with the expression regulation of the NOD-like receptor protein 3 inflammasome. In a lipopolysaccharide-induced acute lung injury model, changes in the polarisation state of macrophages were observed in the compound-treated group.

Lee etアル[6] found that the expression of NF-κB signalling pathway-related molecules was altered in the Hederagenin-treated group. Experimental data suggest that this compound may participate in regulating the expression of inflammatory factors such as nitric oxide synthase and cyclooxygenase-2.

Kim etアル[7] investigated the role of Hederagenin in an alcoholic liver injury model, and experimental data showed changes in the expression levels of inflammatory mediators in the Hederagenin-treated group. Shen etアル[8] observed a potential association between Hederagenin and the tyrosine kinase 2/signal transduction and transcription activator (STAT)3/MAPK signalling pathway, while also detecting changes in the expression levels of inflammatory-related cytokines.

Yu etアル[9] demonstrated that Hederagenin may participate in regulating signaling pathways such as NF-κB, MAPK, and phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt). Experimental results showed differences in the gene expression levels of apoptosis-related markers and inflammatory cytokines in the treatment group.

These studies suggest that Hederagenin may interact with multiple inflammation-related signalling pathways, with factors such as the IL family and tumour necrosis factor α potentially serving as regulatory targets in its action process.

2 Research Progress on Hederagenin Derivatives from Ivy Extracts

Due to the limitations of Hederagenin's physicochemical properties, researchers have explored its derivatives. Among these, α-Hederagenin, as a natural product molecule, has received significant attention [22].

Fang et al. [27] found that the expression of Sirtuin 6 protein changed in the α-Hederagenin-treated group, and simultaneously observed alterations in the expression levels of hypoxia-inducible factor 1α and c-Myc genes, which are regulators of glycolysis. Experimental data showed that the expression levels of glycolysis-related proteins also exhibited corresponding changes.

呉et al. [28] investigated the potential association between α-Hederagenin and the glutathione synthase/glutathione/glutathione peroxidase 2 system. Experimental results indicated that this compound may influence the oxidative stress state of non-small 細胞and exhibit certain interactions with cisplatin [29-30].

Chen et al. [31] revealed a potential link between α-Hederagenin and the Hippo signalling pathway. Data showed that the phosphorylation levels of Yes-related protein upstream kinase macrophage-stimulated 1 and L-type amino acid transporter were altered in the compound-treated group, while the cellular localisation of Yes-related protein also changed.

3 Broad Application Prospects

Existing research has explored Hederagenin and its derivatives from ivy extracts in multiple aspects. Hederagenin, an ivy saponin, demonstrates application potential in various health fields and may be suitable for developing functional products in the following areas:

respiratory health support, joint comfort and health, liver protection, neural health and protection, metabolic and oxidative stress regulation, etc.

Green Spring Technology is committed to providing customers with high-quality raw materials based on scientific research. We deeply understand the importance of plant extract raw materials in end products. Green Spring Technology has a strict quality control system to ensure the purity, active ingredient content, and batch-to-batch stability of raw materials.

Our production and quality management systems strictly adhere to international standards (EP, USP, JP), ensuring that products comply with regulatory requirements in major export markets.

Customised solutions:We can provide Ivy Leaf Extract Powder Hederagenin-related raw materials in different specifications and with stability support to assist you in developing new product formulations based on your specific needs.

Please contact us at helen@greenspringbio.com.

参照

黄[1]曽J、T、薛鉉 現在は、開発・販売を担当している as  a  有望 薬用成分: 総合レビュー[j]。 rsc adv, 2018, 8(43): 24188-24202。 土井: 10 .1039年/ c8ra03666g。

[2]張D 太陽 J ヤン B  et  al.   治療 効果 慢性的な収縮損傷の慢性神経障害性疼痛のテトラパナクスパピリフェルスとヘデラゲニンの of  坐骨 神経ラットは KEGG 経路予測と実験的検証[j]。  基づいてEvid 補数alternat med、2020、2020:2545806。 土井: 10. 1155/2020/2545806。

[3]李Y 董J 商Y et al.   消炎姜正浩- ageninの効果を糖尿病▽心筋症抑制NF -κBとSmads経由でシグナリングパスか[J] type-2糖尿病マウスで専属モデルを務めました。 rsc adv, 2019, 9(45): 26238-26247。 土井: 10 .1039年/ c9ra02043h。

[4]馬雲W 黄 Q ウン G et  al.   の 保護 効果 ヘイル(ヘイル)-ヘイルのこと 肺 線維症 by  regulating  ラットにおけるras / jnk / nfat4軸[j]。 Biosci Biotechnol 逃れ、 ^ a b c d e f g h i 1201 - 1201。 土井: 10 .1080/09168451。見込みだ。1721263。

[5]王 L  Zhao  M。   抑制 of  NOD-like  receptor  タンパク質3インフラマソームの活性化とマクロファージm1 heder- ageninによる分極は、ラットの敗血症誘発性急性肺障害の減衰に寄与する[j]。  バイオ、 平成22年(2022年)3月13日 : 7262-7276。  土井:  10 . 1080/21655979。と見込んだ。2047406。

[6]李 CW、 朴 SM 趙R et  al.   Hederagenin、 a  の主成分の センニンソウ属  viola mandshuricaという  ruprecht  根  減衰  ^アポロドーロス、264話。7 cells  and  マウスで[j]。   Int Immunop - harmacol 2015年 29 局番号は528-537。   土井:  10 .  1016 / j。  intimp。 2015年です10 .002。

[7]金 GJと、 歌 DH、 柳 HS、 et  al.   Hederagenin  補充療法は、ラットでアルコールに対する炎症誘発性およびアポトーシス反応を緩和する[j]。 ^ a b c d e f g h i(2017年)1頁。 土井: 10 .3390 / nu9010041。

[8]申Y 藤代はL 曲 Y et  al.   Hederagenin  を抑える 変形性関節症の進行を改善するための炎症と軟骨の分解:in vivo and  in  体外 研究[j]。   炎症 ^『官報』第2023号、大正6年4月2日。 :  / 655 678 土井: 10 .1007 / s10753-022-01763-5。

すう虞[9] H、宋 Lである故鉠ヨンホさん X, et al.Hederagenin 減衰 mlkを制御する脳虚血・再灌流障害3 を。  pharmacol前[J]。 ^『仙台市史』通史編1、1173頁。 土井: 10 .3389 / fphar。見込みだ。01173。

[10]林Rm、柳 L,シルバ M, et al.Hederagenin 保護 pi3k / akt経路の活性化によるコルチコステロン誘発傷害に対するpc12細胞[j] . front pharmacol,2021,12:712876。土井: 10 . 3389 / fphar。告げてくれ712876。

[11] liang bf, huang f, wang ht,et 抗うつ剤のようなものにおけるノルエピネフリンおよびセロトニン系の関与 効果 hederageninの the   ネズミ モデル of  予測  chronic   軽い  stress-inducedうつ病か[J]。 Pharm Biol、 2015年(平成27年)3月3日閲覧。 : 368-377。   土井:  10 . 3109/13880209。2014922586。

[12]呉 、ドイチェ・バンク、 曽 W 黄 VK  et  al.   Hederagenin  and  α-hederin推進劣化 蛋白質の in  神経変性 病気 そして、mptpマウスの運動障害を改善する[j]。  Pharmacol 「Res publica、 ^ 2017年1月25日、25-44頁。  土井: 10 .1016 / j。phrs。2016年11 .002。

[13]謝z、 趙JP Wu  LM、 et  al.   ヘデラゲニンはアルツハイマー病を改善する を通じて  燃やす働きα/ TFEB-mediated autophagy [J] .    フィト(植物-医学 局番号は1201 - 1201。  土井:  10 . 1016 / j。 phymed。 2023年 154711。